Fervaha, Gagan
Caravaggio, Fernando
Mamo, David C.
Mulsant, Benoit H.
Pollock, Bruce G.
Nakajima, Shinichiro
Gerretsen, Philip
Rajji, Tarek K.
Mar, Wanna
Iwata, Yusuke
Plitman, Eric
Chung, Jun Ku
Remington, Gary
Graff-Guerrero, Ariel
Funding for this research was provided by:
National Institutes of Health (RO1MH084886)
Canadian Institutes of Health Research (MOP-97946)
Article History
Received: 29 May 2016
Accepted: 12 August 2016
First Online: 24 August 2016
Compliance with ethical standards
: The study was approved by the institutional Research Ethics Board, authorized by Health Canada, and registered atExternalRef removed(NCT00716755). All participants had to be deemed competent to provide consent as per the MacArthur Competence Assessment Tool for Clinical Research (Appelbaum and GrissoCitationRef removed) and provided written informed consent before the initiation of any study procedures.
: Dr. Mamo has received research support from Pfizer.Dr. Mulsant has received research support from Brain Canada, Centre for Addiction and Mental Health (CAMH) Foundation, CIHR, US NIH. He has also received medications for NIH-funded clinical trials from Bristol-Myers Squibb, Eli-Lilly and Company, and Pfizer. He directly own stocks of General Electric (<$5000).Dr. Nakajima has received fellowship grants from the CIHR, Japan Society for the Promotion of Science, and Nakatomi Foundation and manuscript fees from Dainippon-Sumitomo Pharma and Kyowa Hakko Kirin.Dr. Gerretsen has received fellowship support from the CAMH Foundation, OMHF, and CIHR.Dr. Rajji received research support from Brain Canada, Brain and Behavior Research Foundation, Canada Research Chair, Canadian Foundation for Innovation, CIHR, Ontario Ministry of Health and Long-Term Care, Ontario Ministry of Research and Innovation, the US NIH, and the W. Garfield Weston Foundation.Dr. Remington has received research support from the Schizophrenia Society of Ontario, CIHR, Research Hospital Fund—Canada Foundation for Innovation, Canadian Diabetes Association, Novartis Canada, Medicure Inc., and Neurocrine Bioscience; as a co-investigator, he has received research support from the Canadian Psychiatric Research Foundation and Pfizer Inc.; consultant fees from Laboratorios Farmacéuticos ROVI, Synchroneuron, Novartis, and Roche; and speaker’s fees from Novartis.Dr. Graff-Guerrero has received support from Brain Canada, Canadian Foundation for Innovation, CIHR, Ontario Ministry of Health and Long-Term Care, Ontario Ministry of Research and Innovation, the US National Institute of Health (NIH), Ontario Mental Health Foundation (OMHF), Consejo Nacional de Ciencia y Tecnologia (CONACyT), Instituto de Ciencia y Tecnología del DF (ICyTDF), and Brain and Behavior Research Foundation.The other authors declare that they have no conflict of interest.